The estimated Net Worth of Geoff Mcdonough is at least $5.2 million dollars as of 15 July 2024. Dr Mcdonough owns over 5,274 units of Generation Bio Co stock worth over $3,258,500 and over the last 5 years he sold GBIO stock worth over $1,083,100. In addition, he makes $856,885 as Pres, CEO et Sec. & Director at Generation Bio Co.
Dr has made over 12 trades of the Generation Bio Co stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 5,274 units of GBIO stock worth $12,869 on 15 July 2024.
The largest trade he's ever made was exercising 46,876 units of Generation Bio Co stock on 15 July 2022 worth over $114,377. On average, Dr trades about 10,381 units every 51 days since 2019. As of 15 July 2024 he still owns at least 1,335,451 units of Generation Bio Co stock.
You can see the complete history of Dr Mcdonough stock trades at the bottom of the page.
Dr. Cameron Geoffrey McDonough is the Pres, CEO, Sec. & Director at Generation Bio Co.
As the Pres, CEO et Sec. & Director of Generation Bio Co, the total compensation of Dr McDonough at Generation Bio Co is $856,885. There are no executives at Generation Bio Co getting paid more.
Dr McDonough is 51, he's been the Pres, CEO et Sec. & Director of Generation Bio Co since . There are 2 older and 2 younger executives at Generation Bio Co. The oldest executive at Generation Bio Co. is Dr. Robert Kotin Ph.D., 65, who is the Co-Founder & Advisor.
Geoff's mailing address filed with the SEC is C/O GENERATION BIO CO., 301 BINNEY ST, , CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Generation Bio Co have traded over $37,722,950 worth of Generation Bio Co stock and bought 4,282,125 units worth $70,408,633 . The most active insiders traders include Jason P Rhodes, Biomedical Innovation Maste... et Public Equities, L.P.Minne .... On average, Generation Bio Co executives and independent directors trade stock every 11 days with the average trade being worth of $116,471. The most recent stock trade was executed by Yalonda Howze on 15 July 2024, trading 3,347 units of GBIO stock currently worth $8,167.
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Generation Bio Co executives and other stock owners filed with the SEC include: